FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 FF301 公司名稱: 百信國際控股有限公司 (於開曼群島註冊成立的有限公司) 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00574 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | HKD | | 0.001 HKD | | | 5,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | | 本月底結存 | | | 5,000,000,000 | HKD | | 0.001 HKD ...

该期间净溢利转为净亏损主要是由于截至2024年6月30日止6个月确认了公司债务重组一次性收益约人民 币4740万元，而该期间并无该一次性收益。 格隆汇7月31日丨百信国际(00574.HK)公告，根据其对集团截至2025年6月30日止6个月("该期间")未经审 核综合管理账目初步评估及董事会现时可得资料，预期集团于该期间将录得净亏损不超过人民币1000万 元，而截至2024年6月30日止6个月的净溢利为人民币3500万元。 ...

百信国际(00574)发布公告，预期集团于截至2025年6月30日止6个月将取得净亏损不超过人民币1000万 元，而截至2024年6月30日止6个月的净溢利为人民币3500万元。该期间净溢利转为净亏损主要是由于截 至2024年6月30日止6个月确认了公司债务重组一次性收益约人民币4740万元，而该期间并无该一次性收 益。 ...

智通财经APP讯，百信国际(00574)发布公告，预期集团于截至2025年6月30日止6个月将取得净亏损不超 过人民币1000万元，而截至2024年6月30日止6个月的净溢利为人民币3500万元。该期间净溢利转为净亏 损主要是由于截至2024年6月30日止6个月确认了公司债务重组一次性收益约人民币4740万元，而该期间 并无该一次性收益。 ...

Pa Shun International Holdings Limited 百信國際控股有限公司 於開曼群島註冊成立的有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公司董事（「董事」）會（「董事會」）謹此通知本公司股東（「股東」）及潛在投資者， 根據其對本集團截至2025年6月30日止六個月（「該期間」）之未經審核綜合管理賬目之初步 評估及董事會現時可得之資料，預期本集團於該期間將錄得淨虧損不超過人民幣10百萬元，而 截至2024年6月30日止六個月的淨溢利為人民幣35百萬元。該期間淨溢利轉為淨虧損主要是由 於截至2024年6月30日止六個月確認了本公司債務重組一次性收益約人民幣47.4百萬元，而該 期間并無該一次性收益。 本公司仍在落實本集團該期間之中期業績。本公佈所載資料僅基於董事會參照本集團該期間之 未經審核綜合管理賬目及董事會現有之其他資料而作出之初步評估，而該等資料可於適當情況 下作出調整，並經董事會及其審核委員會作最後審 ...

格隆汇7月30日丨百信国际(00574.HK)通告，董事会将于2025年8月11日(星期一)举行董事会会议，以考 虑及批准(其中包括)集团截至2025年6月30日止六个月的未经审核中期业绩及其发布，并审议及批准建 议中期股息(如有)。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部分內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任。 （股份代號：574） 董事會會議日期 – 1 – Pa Shun International Holdings Limited 百信國際控股有限公司 （於開曼群島註冊成立的有限公司） 百信國際控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董事會」） 謹此通告，董事會將於2025年8月11日（星期一）舉行董事會會議，以考慮及批准（其中包括） 本集團截至2025年6月30日止六個月之未經審核中期業績及其發佈，並審議及批准建議中期股息 （如有）。 承董事會命 百信國際控股有限公司 主席兼執行董事 袁紅兵 香港，2025年7月30日 於本公佈日期，執行董事為馬清海先生及袁紅兵先生；非執行董事為陳中正先生及周金凱先生； 及獨立非執行董事為李燕女士、婁振業博士及王東源先生。 ...

Company Overview - Baixin International Holdings Limited primarily operates in investment holding, with two main business segments in China: (1) pharmaceutical distribution and (2) pharmaceutical manufacturing [2] Financial Performance - As of December 31, 2024, Baixin International reported total revenue of 86.554 million yuan, a year-on-year decrease of 33.13% [1] - The net profit attributable to shareholders was -15.313 million yuan, reflecting a significant year-on-year decline of 751.62% [1] - The gross profit margin stood at 19.71%, while the debt-to-asset ratio was 175.72% [1] Stock Performance - On July 25, the stock price closed at 0.042 HKD per share, marking an increase of 44.83% with a trading volume of 12.208 million shares and a turnover of 483,900 HKD, showing a volatility of 62.07% [1] - Over the past month, the cumulative increase in stock price was 0%, and the year-to-date decline was 38.3%, underperforming the Hang Seng Index by 27.95% [1] Industry Valuation - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry (TTM) is 3.27 times, with a median of 6.65 times [1] - Baixin International's P/E ratio is -2.59 times, ranking 145th in the industry [1] - Comparatively, other companies in the industry have the following P/E ratios: Qianwei Pharmaceutical (1.22), Kingsray Biotechnology (1.74), Dongrui Pharmaceutical (3.35), Dajiankang International (6.61), and Jilin Changlong Pharmaceutical (6.65) [1]

Financial Performance - The company reported total revenue of approximately RMB 86.6 million for the fiscal year 2024, a decrease of about 33.1% compared to RMB 129.4 million in fiscal year 2023[11]. - The cost of goods sold decreased by approximately 30.6% to about RMB 69.5 million in fiscal year 2024, down from RMB 100.1 million in fiscal year 2023[12]. - Gross profit fell to approximately RMB 17.1 million in fiscal year 2024, a decrease of about 41.6% from RMB 29.3 million in fiscal year 2023, with a gross margin decline from 22.6% to 19.7%[12]. - The company incurred a loss of approximately RMB 15.3 million in fiscal year 2024, compared to a profit of about RMB 2.4 million in fiscal year 2023[20]. - Financing costs increased to approximately RMB 14.8 million in fiscal year 2024, up from RMB 12.9 million in fiscal year 2023[19]. - Selling and distribution expenses rose by approximately 11.1% to about RMB 8.0 million in fiscal year 2024, compared to RMB 7.2 million in fiscal year 2023[14]. - Administrative and other operating expenses decreased significantly by about 38.6% to approximately RMB 14.5 million in fiscal year 2024, down from RMB 23.6 million in fiscal year 2023[15]. - Other income net decreased to approximately RMB 1.5 million in fiscal year 2024, compared to RMB 2.8 million in fiscal year 2023[16]. Corporate Governance - The company continues to review and enhance its corporate governance practices to ensure compliance with the corporate governance code[37]. - The Board is responsible for reviewing and approving significant transactions, investment policies, dividends, and accounting policies[38]. - The company has established four committees (Audit, Nomination, Remuneration, and Corporate Governance) to support the Board, each with a clear written terms of reference[46]. - The board held nine meetings and two annual general meetings during the year ending December 31, 2024[60]. - The nomination committee conducted three meetings to review the board's structure, size, and diversity[55]. - The company has established a code of conduct and compliance manual applicable to employees and directors[57]. - The board's final responsibility for selecting and appointing directors rests with the entire board, despite delegation to the nomination committee[56]. - The company appointed Ms. Lei Meijia as the company secretary on July 15, 2024, who has over 17 years of experience in financial management and corporate financing[68]. Risk Management - The company faces various risks, including compliance risks related to product quality, which could lead to significant financial and reputational damage[123]. - The company has implemented measures to mitigate quality-related risks, such as strict supplier selection and regular quality assessments[124]. - Strategic risks associated with acquisitions include the inability to identify suitable targets and potential undisclosed financial liabilities[126]. - The company emphasizes thorough due diligence and feasibility analysis for acquisition targets to minimize risks[126]. - The board is responsible for establishing and maintaining effective risk management and internal control systems, which are reviewed annually[73]. Debt and Financial Liabilities - The company has faced multiple winding-up petitions since 2020, with a total principal and interest payment of HKD 2,573,424.66 due to bondholders as of 2022[152]. - A debt restructuring plan was approved by the Hong Kong High Court on November 1, 2023, with over 50% of creditors by number and at least 75% by value voting in favor[152]. - The debt repayment arrangement plan is set to take effect on March 12, 2024[152]. - The company submitted a unilateral application to the High Court on July 20, 2023, to convene a meeting for the debt repayment arrangement[152]. Shareholder Engagement - The company held two shareholder meetings during the year ending December 31, 2024, providing opportunities for direct communication between the board and shareholders[87]. - Shareholders have the right to propose special meetings if they hold at least 10% of the paid-up capital, with specific procedures outlined for such requests[91]. - The company aims to provide equal opportunities for all shareholders to exercise their rights and communicate actively[87]. Employee and Management - The group employed 97 staff members as of December 31, 2024, compared to 90 in the previous year, with total employee costs of approximately RMB 8.6 million in fiscal year 2024[30]. - The company has established a remuneration committee to review the remuneration policy considering the group's performance and market practices[173]. - The company has two senior management members with salaries ranging from zero to HKD 1,000,000[51]. Compliance and Regulatory Matters - The company confirmed compliance with the standards for securities trading by all directors during the year ending December 31, 2024[66]. - The independent non-executive directors review compliance with non-competition commitments annually[88]. - The company confirmed compliance with the disclosure requirements under the listing rules regarding related party transactions[188]. Business Strategy - The company continues to focus on the pharmaceutical distribution and manufacturing business in China for fiscal year 2024[10]. - The company has a history of expanding its business through acquisitions and alliances, which remains a key strategic focus[126]. - The management discussion and analysis section of the annual report outlines potential future developments for the business[117]. Dividend Policy - The group did not recommend any final dividend for the fiscal year 2024, consistent with fiscal year 2023[31]. - The company has adopted a dividend policy outlining the procedures for declaring and proposing dividends[101]. - The board will consider factors such as operating performance, cash flow, financial condition, and future prospects when deciding on dividend distribution[105]. - The company emphasizes that past dividend distributions cannot be used as a reference for future dividend levels[103].

Financial Performance - For the six months ended June 30, 2024, the company reported revenue of RMB 48,830,000, a decrease from RMB 82,832,000 in the same period of 2023, representing a decline of approximately 41%[10] - Gross profit for the same period was RMB 9,527,000, down from RMB 20,112,000 in 2023, indicating a decrease of about 53%[10] - The net profit attributable to equity holders for the six months was RMB 35,427,000, significantly up from RMB 4,517,000 in the prior year, reflecting an increase of approximately 684%[12] - The total comprehensive income for the period was RMB 38,585,000, compared to RMB 10,726,000 in 2023, marking an increase of around 259%[12] - The company reported a basic earnings per share of RMB 9 for the current period, compared to RMB 2.4 in the previous year, which is an increase of 275%[13] - The company recognized a debt restructuring gain of RMB 47,356,000 during the period, contributing to the overall profit[10] - Other income for the period was RMB 734,000, compared to a loss of RMB 6,362,000 in the same period last year, indicating a positive turnaround[10] - The company incurred financing costs of RMB 7,281,000, which is a slight decrease from RMB 7,386,000 in the previous year[10] - The foreign exchange gain from the financial statements of overseas entities amounted to RMB 3,158,000, down from RMB 6,209,000 in 2023[12] Assets and Liabilities - As of June 30, 2024, the company's non-current assets totaled RMB 81,024 thousand, a decrease of 1.55% from RMB 82,295 thousand as of December 31, 2023[14] - The company's current assets increased to RMB 132,985 thousand, up 7.8% from RMB 124,271 thousand as of December 31, 2023[14] - Total liabilities decreased to RMB 173,331 thousand as of June 30, 2024, down from RMB 247,744 thousand as of December 31, 2023[15] - The company's cash and cash equivalents decreased to RMB 4,634 thousand, down 72.0% from RMB 16,511 thousand as of December 31, 2023[18] - The company's equity attributable to owners of the company showed a significant improvement, with a loss of RMB (77,514) thousand as of June 30, 2024, compared to a loss of RMB (116,099) thousand as of December 31, 2023[15] Revenue Breakdown - Revenue from pharmaceutical distribution was RMB 33,267 thousand, down 53% from RMB 71,472 thousand year-on-year[24] - Revenue from pharmaceutical production increased to RMB 15,563 thousand, up 37% from RMB 11,360 thousand in the previous year[24] Cash Flow and Operating Activities - The company reported a net cash outflow from operating activities of RMB (14,548) thousand for the six months ended June 30, 2024, compared to a cash inflow of RMB 5,500 thousand for the same period in 2023[18] Corporate Governance and Compliance - The company has adopted a corporate governance code to enhance shareholder value and accountability, ensuring compliance with listing rules regarding independent non-executive directors and committee compositions[66] - Following the resignation of several directors, the company had only two independent non-executive directors until new appointments were made on May 20, 2024, restoring compliance with listing rules[67] - The audit committee, consisting of three independent non-executive directors, is responsible for overseeing financial policies and internal controls, having reviewed the interim financial statements for the six months ending June 30, 2024[68] Share Option Scheme - The company has implemented a share option scheme since May 26, 2015, aimed at rewarding and retaining key contributors to the group's performance and growth[71] - The maximum number of shares that can be issued under the share option scheme is capped at 10% of the issued shares as of the 2019 annual general meeting, which amounts to 147,499,290 shares[73] - As of June 30, 2024, a total of 100,000,000 share options are available for issuance under the share option scheme, representing approximately 6.78% of the company's issued share capital[73] - The exercise price of the share options granted is set at HKD 0.67, with the exercise period from September 7, 2018, to May 25, 2025[75] - No share options were granted, exercised, lapsed, or cancelled during the review period[74] Market Outlook and Strategy - The company plans to continue exploring market expansion opportunities and new product development to drive future growth[10] - The management anticipates a recovery in market demand as business activities in China normalize post-pandemic, while also acknowledging increased competition[57] Employee and Operational Metrics - As of June 30, 2024, the group employed 90 staff members, with total employee costs amounting to RMB 3.4 million for the six months ending June 30, 2024, a decrease from RMB 4.8 million for the same period in 2023[63] Other Notable Information - The company did not declare any interim dividend for the six months ended June 30, 2024, consistent with the previous year[34] - The company did not enter into any new lease agreements during the reporting period[38] - The company did not engage in any significant investments, acquisitions, or disposals that require disclosure under the Hong Kong Stock Exchange listing rules during the six months ended June 30, 2024[61] - There have been no significant events known to the board of directors from June 30, 2024, to the date of this interim report[84]